Royal DSM announces partnership with Mile High Labs, entrée into CBD market

Royal DSM has entered into a broad commercial partnership with cannabinoid ingredients and finished products manufacturer Mile High Labs.

Royal DSM (Parsippany, NJ) has entered into a broad commercial partnership with cannabinoid ingredients and finished products manufacturer Mile High Labs. With Mile High Labs’ large-scale 400,000 square feet of manufacturing facilities, the partnership will enable DSM to apply its advances scientific, applications, and formulations expertise to combine CBD and hemp derivatives with high quality micronutrients to develop market-ready and premix solutions.

“DSM has the core competencies, combined with a deep understanding of consumer and customer needs, to help brands enter the cannabinoid market early and build a leading position. Our science-backed solutions will deliver the purity, reliability and traceability that are currently lacking and enable our customers to truly differentiate themselves,” said Frederic Boned, vice president, human nutrition & health at DSM North America, in a press release. “MHL is the ideal partner due to its staunch commitment to sustainability, quality and regulatory compliance, as well as its extensive cannabinoid manufacturing capabilities. Together, we are committed to developing the standards the cannabinoid industry sorely needs. Our complementary areas of expertise will support customers along the entire product development process.”

“MHL is excited to team up with such a credible player in human nutrition and health, and one that so closely aligns with our ambitions to uncover the full potential of this space,” added Jonathan Hilley, CEO at MHL. “This partnership is an important milestone in the evolution of MHL and a defining moment for our industry. We look forward to pooling our expertise to deliver cannabinoid innovation that is scalable, sustainable, cost-effective and provides the building blocks for exciting new consumer products.”